Sales Reach 153.3 Billion Won as All Business Segments Achieve Balanced Growth

Operating Margin at 12.6%...Improved Results in Chemical, Biopharmaceutical, and CMO Divisions

On August 4, Celltrion Pharmaceutical announced through a provisional earnings disclosure that its sales for the second quarter of this year reached 153.3 billion won, with operating profit totaling 19.3 billion won. Compared to the same period last year, sales increased by 16.8% and operating profit rose by 24.4%. The operating profit also marked the highest quarterly figure in the company’s history.

Celltrion Pharmaceutical company logo image. Celltrion Pharmaceutical

Celltrion Pharmaceutical company logo image. Celltrion Pharmaceutical

View original image

The operating margin for the second quarter came to 12.6%, up 0.8 percentage points from a year earlier. The company attributed its improved performance to stable sales of chemical pharmaceuticals, the expansion of biosimilar prescriptions, and increased global demand, which has led to higher production volumes of pre-filled syringes (PFS).


Cumulative sales for the first half of the year totaled 285.4 billion won, with operating profit reaching 32.2 billion won, representing increases of 17.1% and 22.7%, respectively, compared to the same period last year. Net profit for the same period rose 22.4% to 22.5 billion won, maintaining a stable growth trend.


Sales from the chemical business segment came in at 67.0 billion won. The company’s flagship liver disease treatment, Godex, posted sales of 17.7 billion won—an increase of 10.1% year-on-year—on the back of expanded prescriptions. Diabetes therapies Nesina and Actos continued to generate steady demand, while the newly launched combination antihypertensive and cholesterol medication Amloget achieved sales of 8.6 billion won, up 4.2% from a year prior, benefiting from market expansion. Other products also maintained solid sales performance, underpinning stable results.


Sales from the biopharmaceutical business segment totaled 36.6 billion won, up 12.5% year-on-year. The autoimmune disease treatment Remsima saw its sales rise 19.2% to 11.5 billion won, while blood cancer therapy Truxima generated 4.3 billion won, up 20.7%. The autoimmune disease therapy Yuflyma posted growth of 28.6% to 2.4 billion won, and the anticancer drug Begzelma surged by 93.9% to 4.0 billion won. Sales of the allergy treatment Omriclo soared by 206.5% to 1.2 billion won thanks to expanded new prescriptions at major hospitals. Additional autoimmune disease treatments Steqima and Aptosma each recorded 400 million won in sales, further contributing to the growth of the biopharmaceutical business.


The contract manufacturing organization (CMO) segment posted sales of 49.7 billion won, representing a 53.4% increase from a year earlier. The company’s commercial production revenue for PFS products climbed 51.9% to 35.3 billion won due to rising global demand and higher output. The expansion of in-house product manufacturing and other pharmaceutical service sales also supported the segment’s growth.



A Celltrion Pharmaceutical official stated, "In the second quarter, the growth momentum remained strong across all major business lines, resulting in improved sales and profitability. In the second half of the year, we will continue to enhance the sales competitiveness of key products and flexibly operate production capacity to respond to market demand, thereby maintaining a solid foundation for stable growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing